

Jaime Espin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1100613/publications.pdf>

Version: 2024-02-01

22
papers

360
citations

933447

10
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

537
citing authors

#	ARTICLE	IF	CITATIONS
1	Public health policies for the common interest: rethinking EU states'™ incentives strategies when a pandemic reshuffles all interests. <i>European Journal of Health Economics</i> , 2022, 23, 329-335.	2.8	4
2	Costing methodologies in European economic evaluation guidelines: commonalities and divergences. <i>European Journal of Health Economics</i> , 2022, 23, 979-991.	2.8	2
3	How innovation can be defined, evaluated and rewarded in health technology assessment. <i>Health Economics Review</i> , 2022, 12, 1.	2.0	16
4	Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database. <i>European Journal of Health Economics</i> , 2022, 23, 1563-1575.	2.8	3
5	Description of day case costs and tariffs of cataract surgery from a sample of nine European countries. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, 11.	1.5	3
6	Medicines pricing and reimbursement: innovation, competitiveness, and access. <i>Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde</i> , 2022, 13, 679.	0.1	0
7	Development of the European Healthcare and Social Cost Database (EU HCSCD) for use in economic evaluation of healthcare programs. <i>BMC Health Services Research</i> , 2022, 22, 405.	2.2	1
8	Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications. <i>Frontiers in Pharmacology</i> , 2022, 13, 815029.	3.5	7
9	Cost transferability problems in economic evaluation as a framework for an European health care and social costs database. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 43.	1.5	8
10	Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. <i>Pharmacoeconomics</i> , 2021, 39, 1021-1044.	3.3	23
11	Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 42.	1.5	5
12	Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 57.	1.5	7
13	Evaluation of new medicines in Spain and comparison with other European countries. <i>Gaceta Sanitaria</i> , 2020, 34, 133-140.	1.5	18
14	Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. <i>Clinical Drug Investigation</i> , 2020, 40, 305-318.	2.2	15
15	A general framework for classifying costing methods for economic evaluation of health care. <i>European Journal of Health Economics</i> , 2020, 21, 529-542.	2.8	44
16	A multi-stakeholder approach in optimising patients'™ needs in the benefit assessment process of new metastatic breast cancer treatments. <i>Breast</i> , 2020, 52, 78-87.	2.2	7
17	Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 803-817.	2.1	16
18	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1298190.	1.5	13
20	Risk of second cancers cancer after a first primary breast cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2015, 136, 158-171.	1.4	84
21	Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2014, 23, 721-742.	2.2	67
22	All you need to know about innovation in healthcare: The 10 best reads. <i>International Journal of Healthcare Management</i> , 2012, 5, 193-202.	2.0	11